Recently Featured

AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals

February 12, 2026
AbbVie has entered into a landmark $100 billion agreement that will see the company lower prices on select Medicaid drugs while simultaneously expanding its distribution through the TrumpRx direct-to-patient platform. This strategic move is indicative of a broader trend within the pharmaceutical industry, where companies are increasingly focusing on aligning drug pricing with domestic manufacturing…

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug

January 27, 2026
The Trump administration is set to launch two pilot programs aimed at implementing ‘most favored nation’ pricing for Medicare, which would align U.S. drug costs and rebates with those in comparable countries. This initiative represents a significant shift in the U.S. healthcare landscape, potentially impacting drug pricing strategies across the pharmaceutical industry. By tying Medicare…

Symbiosis Begins Commercial Manufacturing at New FDA-Inspected Facility

January 27, 2026
Symbiosis Pharmaceutical Services (Symbiosis) has successfully manufactured its first batch of 10,000 vials at its newly established facility in Stirling, UK. This milestone production, commissioned by a long-standing client, is pivotal in supporting the development of a cancer immunotherapy currently undergoing Phase III trials. The launch of this facility aligns with Symbiosis’ strategic expansion of…

Medicus Pharma Partners with Reliant AI to Enhance Clinical Trial Analytics

January 27, 2026
Medicus Pharma Ltd. has announced a non-binding letter of intent (LOI) with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at optimizing clinical trial execution. This collaboration is poised to leverage Reliant AI’s generative AI capabilities to provide data-driven insights that could significantly enhance the efficiency and effectiveness of clinical trials.…

Ongoing Cases